Pacer Advisors Inc. Has $347.98 Million Holdings in CVS Health Corporation $CVS

Pacer Advisors Inc. boosted its stake in CVS Health Corporation (NYSE:CVS) by 1,020.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 4,845,221 shares of the pharmacy operator’s stock after buying an additional 4,412,882 shares during the period. Pacer Advisors Inc.’s holdings in CVS Health were worth $347,984,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Pine Valley Investments Ltd Liability Co boosted its stake in shares of CVS Health by 4.2% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 18,820 shares of the pharmacy operator’s stock valued at $1,352,000 after purchasing an additional 763 shares in the last quarter. DV Trading LLC increased its position in shares of CVS Health by 213.2% during the 1st quarter. DV Trading LLC now owns 3,000 shares of the pharmacy operator’s stock worth $215,000 after purchasing an additional 2,042 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of CVS Health by 7.5% in the first quarter. Parallel Advisors LLC now owns 12,478 shares of the pharmacy operator’s stock valued at $896,000 after acquiring an additional 869 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of CVS Health by 21.6% in the 1st quarter. NewEdge Advisors LLC now owns 130,922 shares of the pharmacy operator’s stock worth $9,403,000 after acquiring an additional 23,233 shares in the last quarter. Finally, First Nebraska Trust Co bought a new stake in CVS Health during the 1st quarter worth approximately $488,000. 80.66% of the stock is owned by institutional investors.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Wall Street’s generally bullish recommendations continue to support the investment case, suggesting analysts see further upside in CVS Health’s healthcare-services and pharmacy businesses. Is It Worth Investing in CVS Health Based on Wall Street’s Bullish Views?
• Positive Sentiment: CVS Health’s upcoming second-quarter results are being watched for evidence that revenue, earnings, medical costs, and other key operating metrics remain on track. The company previously reported a strong earnings beat and reaffirmed fiscal 2026 EPS guidance of $7.30 to $7.50, providing a positive fundamental backdrop. CVS Health Q2 Earnings: Wall Street’s Insights on Key Metrics
• Positive Sentiment: New availability of pet medications through CVS Pharmacy could modestly expand pharmacy traffic and customer convenience, although the financial impact is likely limited initially. Pet Medications Now Available at CVS Pharmacy

CVS Health Trading Up 0.1%

CVS stock opened at $104.54 on Monday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a twelve month low of $61.19 and a twelve month high of $110.68. The company has a market cap of $133.39 billion, a P/E ratio of 46.05, a PEG ratio of 1.02 and a beta of 0.61. The business has a fifty day moving average of $101.45 and a 200-day moving average of $87.08.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s payout ratio is 117.18%.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the sale, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. Insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on CVS shares. TD Cowen lifted their price objective on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Bank of America raised their target price on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Mizuho lifted their price target on CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Robert W. Baird increased their price objective on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Finally, HSBC restated a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a research report on Monday, July 6th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.67.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.